Clinical Trial Update: Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005 [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study assessing the extent of systemic absorption of PEP005 in actinic keratoses has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratoses

Drugs mentioned

• PEP005 (ingenol mebutate)

Snippet

Sponsor: Peplin | Conditions: Actinic Keratoses | Phase 1 | Status: COMPLETED